TORONTO, July 17 /CNW/ - Transition Therapeutics Inc. ("Transition") (TSX: TTH - News), announced today that it has regained exclusive ownership of the GLP1-I.N.T.(TM) technology and is moving forward with a clinical development plan to rapidly advance GLP1-I.N.T.(TM) (combination therapy of Transition's regenerative agent G1 and a GLP-1 analogue) into diabetes patients. A conference call will be held at 8:30am EST on Tuesday, July 18th, 2006. The conference call can be accessed by dialing (416) 641-6707 or 1 (800) 263-9150. To participate, please dial the conference number 15 minutes prior to the beginning of the call. An audio web cast of the event will also be available at www.transitiontherapeutics.com.
